spironolactone

ATHENA-HF Trial: High-Dose Spironolactone in Acute Heart Failure

The ATHENA-HF trial, published in JAMA Cardiology in 2017, evaluated the efficacy and safety of high-dose spironolactone in patients with acute heart failure (AHF). This was a double-blind, placebo-controlled randomized clinical trial, aiming to assess whether high-dose spironolactone could significantly … Read More

AMBER Trial: Patiromer to Allow Spironolactone use in Resistant Hypertension

Resistant hypertension poses a significant challenge, especially in patients with chronic kidney disease (CKD). The AMBER trial emerges as a beacon of hope, evaluating the role of the potassium binder patiromer in enabling the use of spironolactone in this difficult-to-treat … Read More

Landmark Clinical Trials of Aldosterone Antagonists

landmark clinical trials focusing on aldosterone antagonists (mineralocorticoid receptor antagonists) like spironolactone and eplerenone, which are commonly used in heart failure and other conditions: 1. RALES (1999) • Title: Randomized Aldactone Evaluation Study • Focus: Heart failure with reduced ejection … Read More

BARACK-D Trial: Spironolactone in CKD

BARACK-D Trial: Low-Dose Spironolactone and Cardiovascular Outcomes in Moderate Stage Chronic Kidney Disease The BARACK-D trial is a prospective, randomized, open, blinded endpoint study that investigates the effects of low-dose spironolactone in patients with stage 3b chronic kidney disease (CKD) … Read More

The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction

Heart failure with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent form of heart failure, accounting for nearly half of all heart failure cases. Despite its significance, HFpEF remains a challenging condition to manage and treat, as effective … Read More